← Back to search

ESPERION THERAPEUTICS, INC.

ESPR · NASDAQ

Pharmaceutical Preparation Manufacturing

Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make a substantial impact on reducing global cardiovascular disease, the leading cause of death around the world.

ESG Scores

Overall ESG
3.2
Environmental
2.4
Social
2.2
Governance
5.6

Gender Diversity

Female Directors0.2%
CEO GenderMale

Market Data

Price$3.14+0.00 (+0.00%)
Market Cap$808M
P/E Ratio
EPS$—
52W High$4.18
52W Low$0.91
Beta1.12